Celcuity https://validator.w3.org/feed/docs/rss2.html Celcuity Appoints Eldon Mayer as Chief Commercial Officer Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Breast Cancer Models at the 2023 San Antonio Breast Cancer Symposium Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Webcast/Conference Call Celcuity to Participate in Leerink Partners Global Biopharma Conference 2024 Celcuity to Participate in Cowen’s 44th Annual Health Care Conference Celcuity Announces First Patient Dosed in Phase 1b/2 CELC-G-201 Clinical Trial of Gedatolisib for the Treatment of Metastatic Castration Resistant Prostate Cancer Celcuity Inc. Reports First Quarter Financial Results and Provides Corporate Update Celcuity Inc. Schedules Release of First Quarter 2024 Financial Results and Webcast/Conference Call Celcuity To Present at Upcoming Needham and Stifel Investor Conferences Celcuity Inc. Schedules Release of Second Quarter 2024 Financial Results and Webcast/Conference Call Celcuity To Participate in Jefferies Global Healthcare Conference Celcuity Announces Pricing of Underwritten Common Stock Offering Celcuity Inc. Announces Plan to Initiate a Phase 3 Clinical Trial for Gedatolisib as First-Line Treatment for HR+/HER2- Advanced Breast Cancer and Secures Approximately $62 Million Debt Financing Celcuity Inc. To Present at Upcoming Stifel and Jefferies Investor Conferences Celcuity Inc. Schedules Release of Third Quarter 2024 Financial Results and Webcast/Conference Call Celcuity Inc. Reports Second Quarter Financial Results and Provides Corporate Update Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2024 Financial Results and Webcast/Conference Call Celcuity to Participate at Upcoming Cowen and Leerink Investor Conferences Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer Symposium Celcuity Inc. Reports Third Quarter Financial Results and Provides Corporate Update Celcuity Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update Celcuity Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update Celcuity Inc. Schedules Release of First Quarter 2025 Financial Results and Webcast/Conference Call Celcuity To Present at Upcoming Needham and Stifel Investor Conferences Celcuity Announces Issuance of New Patent for Gedatolisib that Extends Patent Exclusivity into 2042 Celcuity Reports Clinical Data from Two Early Phase Studies of Gedatolisib Celcuity To Present at Upcoming TD Cowen and Jefferies Investor Conferences Senior Medical Director Senior Medical Director, Drug Safety and Pharmacovigilance Senior or Principal Scientist, Formulation and Process Development Senior Quality Assurance Auditor Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-2 Clinical Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer Lab Systems Manager Associate Scientist, Cell Signaling and Assay Development Batch Record Specialist Director, Medical Science Liaison, Carolinas Director, Medical Science Liaison, North Central Director or Senior Director, API Development Executive Director, Regulatory Affairs, Global Director, National Accounts and Field Reimbursement Celcuity Inc. Schedules Release of Second Quarter 2025 Financial Results and Webcast/Conference Call Celcuity Inc. Announces Pricing of Concurrent Public Offerings of 2.750% Convertible Senior Notes Due 2031 and Common Stock and Pre-Funded Warrants Celcuity Inc. Announces Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock Celcuity to Announce Topline Results for the PIK3CA Wild-Type Cohort from Phase 3 VIKTORIA-1 Trial in HR+/HER2- Advanced Breast Cancer Celcuity Announces Clinically Meaningful Improvement in Both Progression-Free Survival (“PFS”) Primary Endpoints from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial Accounting Manager Associate Director, Drug Safety and Pharmacovigilance Associate Director, Market Access Analytics Block Pam. Unlock Tomorrow